BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
Full Text:
Database and Peer Reviewed Publications
Hartung, D. M., Zarin, D. A., Guise, J. M., McDonagh, M., Paynter
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
Background: Academic medical centers are examining relationships with the pharmaceutical industry
and making changes to limit interactions. Most doctors, however, practice outside of academic institutions
and see pharmaceutical detailers and accept drug samples and gifts. Little guidance for practicing
physicians exists about transforming practices to become pharma-free. Consideration must be...
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX)
may provide an advantage over other oral agents approved for alcohol and opioid dependence
treatment. The objective of this study was to evaluate cost and utilization outcomes between
XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence.
Published studies were...